OA11673A - New controlled release bead, a method of producingthe same and multiple unit formulation comprising it. - Google Patents

New controlled release bead, a method of producingthe same and multiple unit formulation comprising it. Download PDF

Info

Publication number: OA11673A
Authority: OA; OAPI
Prior art keywords: layer; bead according; daims; bead; tolterodine
Prior art date: 1998-11-11

Application number

OA1200100112A

Other languages

English (en)

Inventor

Torkel Gren

Anders Ringberg

Randy J Wald

Martin Wikberg

Original Assignee

Pharmacia Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-11-11

Filing date

1999-11-11

Publication date

2005-01-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20413266&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA11673(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-08-26 Priority claimed from PCT/SE1999/001463 external-priority patent/WO2000012069A1/en

1999-11-11 Application filed by Pharmacia Ab filed Critical Pharmacia Ab

2005-01-12 Publication of OA11673A publication Critical patent/OA11673A/en

Links

239000011324 bead Substances 0.000 title claims abstract description 70
238000013270 controlled release Methods 0.000 title claims abstract description 30
238000000034 method Methods 0.000 title claims abstract description 12
239000000203 mixture Substances 0.000 title claims description 27
238000009472 formulation Methods 0.000 title claims description 14
229920000642 polymer Polymers 0.000 claims abstract description 22
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
239000000463 material Substances 0.000 claims abstract description 11
229920003176 water-insoluble polymer Polymers 0.000 claims abstract description 7
239000003814 drug Substances 0.000 claims description 42
229940079593 drug Drugs 0.000 claims description 41
OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 claims description 30
229960004045 tolterodine Drugs 0.000 claims description 28
BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 claims description 28
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 26
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 26
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 26
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 26
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 26
150000001875 compounds Chemical class 0.000 claims description 10
239000001856 Ethyl cellulose Substances 0.000 claims description 9
229920001249 ethyl cellulose Polymers 0.000 claims description 9
235000019325 ethyl cellulose Nutrition 0.000 claims description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
239000002775 capsule Substances 0.000 claims description 8
206010020853 Hypertonic bladder Diseases 0.000 claims description 7
208000009722 Overactive Urinary Bladder Diseases 0.000 claims description 7
-1 methoxy, hydroxy, hydroxymethyl Chemical group 0.000 claims description 7
208000020629 overactive bladder Diseases 0.000 claims description 5
229940002612 prodrug Drugs 0.000 claims description 5
239000000651 prodrug Chemical group 0.000 claims description 5
150000001412 amines Chemical class 0.000 claims description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
229910052757 nitrogen Inorganic materials 0.000 claims description 4
208000018522 Gastrointestinal disease Diseases 0.000 claims description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
239000011230 binding agent Substances 0.000 claims description 3
238000000338 in vitro Methods 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
239000002253 acid Substances 0.000 claims description 2
150000007513 acids Chemical class 0.000 claims description 2
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 2
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
125000004432 carbon atom Chemical group C* 0.000 claims description 2
125000005842 heteroatom Chemical group 0.000 claims description 2
125000001183 hydrocarbyl group Chemical group 0.000 claims description 2
229910052739 hydrogen Inorganic materials 0.000 claims description 2
239000001257 hydrogen Substances 0.000 claims description 2
206010029446 nocturia Diseases 0.000 claims description 2
230000003287 optical effect Effects 0.000 claims description 2
229920005596 polymer binder Polymers 0.000 claims description 2
239000002491 polymer binding agent Substances 0.000 claims description 2
125000001302 tertiary amino group Chemical group 0.000 claims description 2
229920003169 water-soluble polymer Polymers 0.000 claims description 2
125000003118 aryl group Chemical group 0.000 claims 2
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 1
229910052736 halogen Inorganic materials 0.000 claims 1
150000002367 halogens Chemical class 0.000 claims 1
239000002861 polymer material Substances 0.000 claims 1
239000004480 active ingredient Substances 0.000 abstract 2
230000035515 penetration Effects 0.000 abstract 1
239000010410 layer Substances 0.000 description 54
239000011162 core material Substances 0.000 description 32
TWHNMSJGYKMTRB-KXYUELECSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;2-[(1r)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 TWHNMSJGYKMTRB-KXYUELECSA-N 0.000 description 13
239000011248 coating agent Substances 0.000 description 13
238000000576 coating method Methods 0.000 description 13
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 6
239000001863 hydroxypropyl cellulose Substances 0.000 description 6
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 6
239000000243 solution Substances 0.000 description 6
229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
239000001267 polyvinylpyrrolidone Substances 0.000 description 5
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
235000010980 cellulose Nutrition 0.000 description 4
229920001477 hydrophilic polymer Polymers 0.000 description 4
239000012528 membrane Substances 0.000 description 4
238000002156 mixing Methods 0.000 description 4
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 3
230000007423 decrease Effects 0.000 description 3
238000010586 diagram Methods 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
238000001035 drying Methods 0.000 description 3
230000000694 effects Effects 0.000 description 3
230000004941 influx Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000004014 plasticizer Substances 0.000 description 3
229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
229920000193 polymethacrylate Polymers 0.000 description 3
239000008213 purified water Substances 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
239000001069 triethyl citrate Substances 0.000 description 3
235000013769 triethyl citrate Nutrition 0.000 description 3
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
206010036018 Pollakiuria Diseases 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
239000004372 Polyvinyl alcohol Substances 0.000 description 2
241000206607 Porphyra umbilicalis Species 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 2
208000000921 Urge Urinary Incontinence Diseases 0.000 description 2
208000021017 Weight Gain Diseases 0.000 description 2
229940081735 acetylcellulose Drugs 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
229920002301 cellulose acetate Polymers 0.000 description 2
229940081734 cellulose acetate phthalate Drugs 0.000 description 2
239000003240 coconut oil Substances 0.000 description 2
235000019864 coconut oil Nutrition 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
201000003146 cystitis Diseases 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
239000004205 dimethyl polysiloxane Substances 0.000 description 2
235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
229960004667 ethyl cellulose Drugs 0.000 description 2
238000013265 extended release Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
239000002198 insoluble material Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000004816 latex Substances 0.000 description 2
229920000126 latex Polymers 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
238000004987 plasma desorption mass spectroscopy Methods 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920002451 polyvinyl alcohol Polymers 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
230000002048 spasmolytic effect Effects 0.000 description 2
238000005507 spraying Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
208000022934 urinary frequency Diseases 0.000 description 2
230000036318 urination frequency Effects 0.000 description 2
230000004584 weight gain Effects 0.000 description 2
235000019786 weight gain Nutrition 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
DUXZAXCGJSBGDW-FQEVSTJZSA-N 2-[(1s)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenol Chemical compound C1([C@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)O)=CC=CC=C1 DUXZAXCGJSBGDW-FQEVSTJZSA-N 0.000 description 1
OOGJQPCLVADCPB-FQEVSTJZSA-N 2-[(1s)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol Chemical compound C1([C@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-FQEVSTJZSA-N 0.000 description 1
KISZTEOELCMZPY-UHFFFAOYSA-N 3,3-diphenylpropylamine Chemical class C=1C=CC=CC=1C(CCN)C1=CC=CC=C1 KISZTEOELCMZPY-UHFFFAOYSA-N 0.000 description 1
ZAMLGGRVTAXBHI-UHFFFAOYSA-N 3-(4-bromophenyl)-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(CC(O)=O)C1=CC=C(Br)C=C1 ZAMLGGRVTAXBHI-UHFFFAOYSA-N 0.000 description 1
QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
206010071445 Bladder outlet obstruction Diseases 0.000 description 1
DUXZAXCGJSBGDW-HXUWFJFHSA-N Desfesoterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)O)=CC=CC=C1 DUXZAXCGJSBGDW-HXUWFJFHSA-N 0.000 description 1
PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 1
XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
229920003163 Eudragit® NE 30 D Polymers 0.000 description 1
229920003157 Eudragit® RL 30 D Polymers 0.000 description 1
229920003161 Eudragit® RS 30 D Polymers 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
206010027566 Micturition urgency Diseases 0.000 description 1
241000275031 Nica Species 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
208000003800 Urinary Bladder Neck Obstruction Diseases 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
229920003064 carboxyethyl cellulose Polymers 0.000 description 1
229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
229920006217 cellulose acetate butyrate Polymers 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
229940116592 central nervous system diagnostic radiopharmaceuticals Drugs 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
239000011247 coating layer Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000001934 delay Effects 0.000 description 1
229940099371 diacetylated monoglycerides Drugs 0.000 description 1
229960002380 dibutyl phthalate Drugs 0.000 description 1
229940031954 dibutyl sebacate Drugs 0.000 description 1
238000007922 dissolution test Methods 0.000 description 1
206010013781 dry mouth Diseases 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
239000001087 glyceryl triacetate Substances 0.000 description 1
235000013773 glyceryl triacetate Nutrition 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
229940127022 high-dose drug Drugs 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
230000007794 irritation Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229940117841 methacrylic acid copolymer Drugs 0.000 description 1
229920003145 methacrylic acid copolymer Polymers 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000003607 modifier Substances 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
125000006574 non-aromatic ring group Chemical group 0.000 description 1
230000002536 noncholinergic effect Effects 0.000 description 1
229960005434 oxybutynin Drugs 0.000 description 1
239000008188 pellet Substances 0.000 description 1
210000004197 pelvis Anatomy 0.000 description 1
PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
230000008569 process Effects 0.000 description 1
201000004240 prostatic hypertrophy Diseases 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
201000007608 radiation cystitis Diseases 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
229920002379 silicone rubber Polymers 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229920001169 thermoplastic Polymers 0.000 description 1
239000004416 thermosoftening plastic Substances 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1
WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
125000005591 trimellitate group Chemical group 0.000 description 1
206010046494 urge incontinence Diseases 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Dermatology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

OA1200100112A 1998-11-11 1999-11-11 New controlled release bead, a method of producingthe same and multiple unit formulation comprising it. OA11673A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9803871A SE9803871D0 (sv)	1998-11-11	1998-11-11	Therapeutic method and formulation
PCT/SE1999/001463 WO2000012069A1 (en)	1998-08-27	1999-08-26	Therapeutic formulation for administering tolterodine with controlled release

Publications (1)

Publication Number	Publication Date
OA11673A true OA11673A (en)	2005-01-12

Family

ID=20413266

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200100112A OA11673A (en)	1998-11-11	1999-11-11	New controlled release bead, a method of producingthe same and multiple unit formulation comprising it.

Country Status (40)

Country	Link
US (1)	US6911217B1 (pl)
EP (1)	EP1128819B1 (pl)
JP (1)	JP3616011B2 (pl)
KR (1)	KR100467384B1 (pl)
CN (1)	CN1169522C (pl)
AP (1)	AP1323A (pl)
AR (1)	AR027815A1 (pl)
AT (1)	ATE247458T1 (pl)
AU (1)	AU762410B2 (pl)
BG (1)	BG65149B1 (pl)
BR (1)	BRPI9915142B8 (pl)
CA (1)	CA2350061C (pl)
CZ (1)	CZ299582B6 (pl)
DE (1)	DE69910604T2 (pl)
DK (1)	DK1128819T3 (pl)
EA (1)	EA005074B1 (pl)
EE (1)	EE05232B1 (pl)
ES (1)	ES2204193T3 (pl)
GE (1)	GEP20022833B (pl)
HK (1)	HK1040917B (pl)
HR (1)	HRP20010333B1 (pl)
HU (1)	HU226582B1 (pl)
ID (1)	ID30039A (pl)
IL (1)	IL142809A0 (pl)
IS (1)	IS2370B (pl)
MA (1)	MA25325A1 (pl)
MY (1)	MY122195A (pl)
NO (1)	NO331399B1 (pl)
NZ (1)	NZ511430A (pl)
OA (1)	OA11673A (pl)
PL (1)	PL195780B1 (pl)
PT (1)	PT1128819E (pl)
RS (1)	RS49891B (pl)
SE (1)	SE9803871D0 (pl)
SI (1)	SI1128819T1 (pl)
SK (1)	SK284758B6 (pl)
TW (2)	TWI222879B (pl)
UA (1)	UA57165C2 (pl)
WO (1)	WO2000027364A1 (pl)
ZA (1)	ZA200103575B (pl)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6310103B1 (en) *	1996-07-19	2001-10-30	Bridge Pharma, Inc.	S(−)-tolterodine in the treatment of urinary and gastrointestinal disorders
US8563522B2 (en)	1997-07-08	2013-10-22	The Iams Company	Method of maintaining and/or attenuating a decline in quality of life
EP0957073A1 (en)	1998-05-12	1999-11-17	Schwarz Pharma Ag	Novel derivatives of 3,3-diphenylpropylamines
DK1227806T3 (da)	1999-11-11	2005-10-31	Pfizer Health Ab	Farmaceutisk præparat indeholdende tolterodin og dets anvendelse
CA2496806A1 (en) *	2002-08-28	2004-03-11	Pharmacia Corporation	Oral liquid tolterodine composition
US8168170B2 (en)	2002-10-03	2012-05-01	The Procter And Gamble Company	Compositions having an inner core and at least three surrounding layers
AU2004206110A1 (en) *	2003-01-22	2004-08-05	Pfizer Health Ab	Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders
DE10315917A1 (de) *	2003-04-08	2004-11-18	Schwarz Pharma Ag	Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
WO2004112756A1 (en)	2003-06-26	2004-12-29	Isa Odidi	Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US8709476B2 (en)	2003-11-04	2014-04-29	Supernus Pharmaceuticals, Inc.	Compositions of quaternary ammonium compounds containing bioavailability enhancers
DE602004030931D1 (pl)	2003-11-04	2011-02-17	Supernus Pharmaceuticals Inc
US8877178B2 (en)	2003-12-19	2014-11-04	The Iams Company	Methods of use of probiotic bifidobacteria for companion animals
US7785635B1 (en)	2003-12-19	2010-08-31	The Procter & Gamble Company	Methods of use of probiotic lactobacilli for companion animals
US20050152884A1 (en)	2003-12-19	2005-07-14	The Procter & Gamble Company	Canine probiotic Bifidobacteria globosum
US8894991B2 (en)	2003-12-19	2014-11-25	The Iams Company	Canine probiotic Lactobacilli
US20050158294A1 (en)	2003-12-19	2005-07-21	The Procter & Gamble Company	Canine probiotic Bifidobacteria pseudolongum
US8394409B2 (en) *	2004-07-01	2013-03-12	Intellipharmaceutics Corp.	Controlled extended drug release technology
US10624858B2 (en)	2004-08-23	2020-04-21	Intellipharmaceutics Corp	Controlled release composition using transition coating, and method of preparing same
EP1629834A1 (en)	2004-08-27	2006-03-01	KRKA, D.D., Novo Mesto	Sustained release pharmaceutical composition of tolterodine
CA2590556A1 (en) *	2005-01-10	2006-07-13	Teva Pharmaceutical Industries Ltd.	Process for preparing tolterodine tartrate
JP4938006B2 (ja)	2005-05-31	2012-05-23	ザ・アイムス・カンパニー	ネコ科動物プロバイオティク・ビフィドバクテリア
EP2261323A1 (en)	2005-05-31	2010-12-15	The Iams Company	Feline probiotic lactobacilli
US10064828B1 (en)	2005-12-23	2018-09-04	Intellipharmaceutics Corp.	Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
DK2997953T3 (en)	2006-01-18	2019-04-15	Intec Pharma Ltd	ADMINISTRATION ORAL ADMINISTRATION
PT3095447T (pt)	2006-02-03	2022-01-24	Opko Renal Llc	Tratamento da insuficiência e deficiência de vitamina d com 25-hidroxivitamina d2 e 25-hidroxivitamina d3
KR100714058B1 (ko) *	2006-02-06	2007-05-02	한국유나이티드제약 주식회사	톨테로딘 엘-주석산염의 서방형 경구투여 조성물 및 이의 제조 방법
MX2008010877A (es) *	2006-02-24	2008-11-25	Teva Pharma	Tabletas de liberacion prolongada de succinato de metroprolol y metodos para su preparacion.
EP1996169A2 (en) *	2006-03-21	2008-12-03	Teva Pharmaceutical Industries Ltd	Controlled release formulation of tolterodine
EP1839649A1 (en) *	2006-03-31	2007-10-03	LEK Pharmaceuticals D.D.	Coated formulations for tolterodine
CN104825397A (zh) *	2006-04-03	2015-08-12	伊萨·奥迪迪	含有机溶胶涂层的受控释放递送物件
EP2015735A1 (en) *	2006-04-21	2009-01-21	Synthon B.V.	Tolterodine beads
US10960077B2 (en)	2006-05-12	2021-03-30	Intellipharmaceutics Corp.	Abuse and alcohol resistant drug composition
WO2007131804A1 (en)	2006-05-17	2007-11-22	Synthon B.V.	Tablet composition with a prolonged release of tamsulosin
DK2037936T3 (da)	2006-06-21	2014-09-22	Opko Renal Llc	Fremgangsmåde til behandling og forebyggelse af sekundær hyperparathyroidisme
JP2008007458A (ja) *	2006-06-29	2008-01-17	Freunt Ind Co Ltd	レイヤリング用核粒子とその製造方法
CA2670636A1 (en)	2006-11-27	2008-06-05	H. Lundbeck A/S	Heteroaryl amide derivatives
WO2008093303A2 (en)	2007-02-01	2008-08-07	The Iams Company	Method for decreasing inflammation and stress in a mammal using glucose antimetaboltes, avocado or avocado extracts
KR101691876B1 (ko)	2007-04-25	2017-01-02	사이토크로마 인코포레이티드	비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
CA2683628C (en)	2007-04-25	2018-03-06	Cytochroma Inc.	Method of treating vitamin d insufficiency and deficiency
ES3047207T3 (en)	2007-04-25	2025-12-03	Opko Renal Llc	Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
CL2008001970A1 (es) *	2007-07-03	2009-03-27	Synthon Bv	Perla con un nucleo de celulosa microcristalina, un recubrimiento soluble en agua con un polimero vinil pirrolidina, una capa con tolterodina y un aglutinante, y una capa de liberacion controlada con un poliacrilato; proceso para prepararla; forma de dosificacion, util en trastornos urinarios como vejiga hiperactiva.
US8110226B2 (en) *	2007-07-20	2012-02-07	Mylan Pharmaceuticals Inc.	Drug formulations having inert sealed cores
US8486452B2 (en)	2007-07-20	2013-07-16	Mylan Pharmaceuticals Inc.	Stabilized tolterodine tartrate formulations
US8871275B2 (en)	2007-08-08	2014-10-28	Inventia Healthcare Private Limited	Extended release compositions comprising tolterodine
CN105534936B (zh)	2007-08-13	2020-07-31	Ohemo 生命科学股份有限公司	抗滥用药物、使用方法和制备方法
US20090192228A1 (en) *	2008-01-28	2009-07-30	Actavis Group Ptc Ehf	Controlled-Release Tolterodine Compositions and Methods
US20090214665A1 (en) *	2008-02-26	2009-08-27	Lai Felix S	Controlled Release Muscarinic Receptor Antagonist Formulation
CA2629099A1 (en) *	2008-04-01	2009-10-01	Pharmascience Inc.	Novel oral controlled release pharmaceutical formulations
ES2593356T3 (es)	2008-04-02	2016-12-07	Opko Ireland Global Holdings, Ltd.	Métodos, composiciones, usos y kits útiles para la deficiencia de la vitamina D y trastornos relacionados
US20090311317A1 (en) *	2008-05-14	2009-12-17	Capricorn Pharma Inc.	Modified release tolterodine formulations
US9771199B2 (en)	2008-07-07	2017-09-26	Mars, Incorporated	Probiotic supplement, process for making, and packaging
US8465770B2 (en)	2008-12-24	2013-06-18	Synthon Bv	Low dose controlled release tablet
WO2011013082A1 (en)	2009-07-31	2011-02-03	Ranbaxy Laboratories Limited	Multi-layered, multiple unit pharmaceutical compositions
US10104903B2 (en)	2009-07-31	2018-10-23	Mars, Incorporated	Animal food and its appearance
WO2011061616A2 (en)	2009-11-23	2011-05-26	Micro Labs Limited	Extended release compositions containing tolterodine and process for preparing the same
WO2011095388A1 (en)	2010-02-04	2011-08-11	Synthon Bv	Tolterodine bead
US11672809B2 (en)	2010-03-29	2023-06-13	Eirgen Pharma Ltd.	Methods and compositions for reducing parathyroid levels
JO3112B1 (ar)	2010-03-29	2017-09-20	Ferring Bv	تركيبة دوائية سريعة التحلل
BR112012024432A2 (pt)	2010-03-29	2016-05-31	Ferring Bv	composição farmacêutica de dissolução rápida
CA2796877A1 (en)	2010-04-30	2011-11-03	Merck Sharp & Dohme Corp.	Novel beta 3 adrenergic receptor agonists
US20120040008A1 (en) *	2010-08-11	2012-02-16	Ashish Chatterji	Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US20120289560A1 (en) *	2011-05-10	2012-11-15	Theravida, Inc.	Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder
GR1007628B (el)	2011-07-27	2012-06-29	Φαρματεν Αβεε,	Φαρμακευτικο σκευασμα περιεχον εναν αντιμουσκαρινικο παραγοντα και μεθοδος για την παρασκευη αυτου
JP6174585B2 (ja)	2011-09-16	2017-08-02	フェリングベスローテンフェンノートシャップ	速溶性医薬組成物
WO2013047795A1 (ja) *	2011-09-30	2013-04-04	アステラス製薬株式会社	粒子状医薬組成物
BR112015000329A2 (pt)	2012-07-12	2017-06-27	Ferring Bv	formulações de diclofenac
HK1213178A1 (zh) *	2012-09-20	2016-06-30	Ohr Pharma, Llc	用於治疗剂的缓释的多层生物可降解的微粒
US20150306170A1 (en) *	2012-11-21	2015-10-29	Ferring B.V.	Composition for immediate and extended release
TW201422254A (zh) *	2012-11-21	2014-06-16	Ferring Bv	用於速釋及延釋的組成物
HUE050303T2 (hu) *	2013-03-13	2020-11-30	Intervet Int Bv	Stabil bioaktív szubsztanciák és eljárások elõállítására
KR101847947B1 (ko)	2013-03-15	2018-05-28	옵코 아이피 홀딩스 Ⅱ 인코포레이티드	안정화되고 변형된 비타민 ｄ 방출 제형
US20140275038A1 (en)	2013-03-15	2014-09-18	Inspirion Delivery Technologies, Llc	Abuse deterrent compositions and methods of use
AU2014246617A1 (en)	2013-12-23	2015-07-09	Sun Pharmaceutical Industries Limited	Multi-layered, multiple unit pharmaceutical compositions
US10220047B2 (en)	2014-08-07	2019-03-05	Opko Ireland Global Holdings, Ltd.	Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
US10729685B2 (en)	2014-09-15	2020-08-04	Ohemo Life Sciences Inc.	Orally administrable compositions and methods of deterring abuse by intranasal administration
CA3018328A1 (en) *	2014-10-31	2016-04-30	Purdue Pharma	Methods and compositions particularly for treatment of attention deficit disorder
WO2017146053A1 (ja) *	2016-02-23	2017-08-31	ニプロ株式会社	医薬組成物粒子とそれを含む口腔内崩壊製剤
KR20180123100A (ko)	2016-03-28	2018-11-14	옵코 아일랜드 글로벌 홀딩스 리미티드	비타민 d 치료 방법
US12303604B1 (en)	2024-10-16	2025-05-20	Currax Pharmaceuticals Llc	Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1144911B (it) *	1981-03-19	1986-10-29	Pharmatec Spa	Composizione farmaceutica a rilascio controllato contenente ibuprofen
JPH07107450A (ja)	1993-10-08	1995-04-21	Hitachi Ltd	情報通信装置
JP3453186B2 (ja)	1994-04-14	2003-10-06	共和薬品工業株式会社	徐放性マイクロカプセルおよびその製造方法
SE9402422D0 (sv) *	1994-07-08	1994-07-08	Astra Ab	New beads for controlled release and a pharmaceutical preparation containing the same
US5645858A (en) *	1994-10-06	1997-07-08	Ortho Pharmaceutical Corporation	Multilayered controlled release pharmaceutical dosage form
US5567441A (en) *	1995-03-24	1996-10-22	Andrx Pharmaceuticals Inc.	Diltiazem controlled release formulation
US6310103B1 (en)	1996-07-19	2001-10-30	Bridge Pharma, Inc.	S(−)-tolterodine in the treatment of urinary and gastrointestinal disorders
US6312728B1 (en) *	1998-07-07	2001-11-06	Cascade Development, Inc.	Sustained release pharmaceutical preparation

1998
- 1998-11-11 SE SE9803871A patent/SE9803871D0/xx unknown
1999
- 1999-11-11 WO PCT/SE1999/002052 patent/WO2000027364A1/en not_active Ceased
- 1999-11-11 IL IL14280999A patent/IL142809A0/xx unknown
- 1999-11-11 DE DE69910604T patent/DE69910604T2/de not_active Expired - Lifetime
- 1999-11-11 MY MYPI99004911A patent/MY122195A/en unknown
- 1999-11-11 AT AT99971702T patent/ATE247458T1/de active
- 1999-11-11 CN CNB998132160A patent/CN1169522C/zh not_active Expired - Lifetime
- 1999-11-11 US US09/763,281 patent/US6911217B1/en not_active Expired - Lifetime
- 1999-11-11 EE EEP200100254A patent/EE05232B1/xx unknown
- 1999-11-11 ES ES99971702T patent/ES2204193T3/es not_active Expired - Lifetime
- 1999-11-11 NZ NZ511430A patent/NZ511430A/en not_active IP Right Cessation
- 1999-11-11 AR ARP990105734A patent/AR027815A1/es active IP Right Grant
- 1999-11-11 PL PL99348612A patent/PL195780B1/pl unknown
- 1999-11-11 PT PT99971702T patent/PT1128819E/pt unknown
- 1999-11-11 HK HK02102521.2A patent/HK1040917B/zh not_active IP Right Cessation
- 1999-11-11 AP APAP/P/2001/002166A patent/AP1323A/en active
- 1999-11-11 ID IDW00200101038A patent/ID30039A/id unknown
- 1999-11-11 JP JP2000580595A patent/JP3616011B2/ja not_active Expired - Lifetime
- 1999-11-11 DK DK99971702T patent/DK1128819T3/da active
- 1999-11-11 UA UA2001042824A patent/UA57165C2/uk unknown
- 1999-11-11 OA OA1200100112A patent/OA11673A/en unknown
- 1999-11-11 GE GEAP19995939A patent/GEP20022833B/en unknown
- 1999-11-11 RS YUP-331/01A patent/RS49891B/sr unknown
- 1999-11-11 CZ CZ20011627A patent/CZ299582B6/cs not_active IP Right Cessation
- 1999-11-11 KR KR10-2001-7005879A patent/KR100467384B1/ko not_active Expired - Lifetime
- 1999-11-11 CA CA002350061A patent/CA2350061C/en not_active Expired - Lifetime
- 1999-11-11 SI SI9930411T patent/SI1128819T1/xx unknown
- 1999-11-11 HR HR20010333A patent/HRP20010333B1/xx not_active IP Right Cessation
- 1999-11-11 EA EA200100538A patent/EA005074B1/ru not_active IP Right Cessation
- 1999-11-11 EP EP99971702A patent/EP1128819B1/en not_active Expired - Lifetime
- 1999-11-11 SK SK625-2001A patent/SK284758B6/sk not_active IP Right Cessation
- 1999-11-11 BR BRPI9915142A patent/BRPI9915142B8/pt not_active IP Right Cessation
- 1999-11-11 HU HU0105038A patent/HU226582B1/hu unknown
- 1999-11-11 AU AU14366/00A patent/AU762410B2/en not_active Expired
2000
- 2000-02-11 TW TW089102338A patent/TWI222879B/zh not_active IP Right Cessation
- 2000-02-11 TW TW089102332A patent/TWI267385B/zh not_active IP Right Cessation
2001
- 2001-05-03 ZA ZA200103575A patent/ZA200103575B/en unknown
- 2001-05-09 IS IS5936A patent/IS2370B/is unknown
- 2001-05-10 NO NO20012314A patent/NO331399B1/no not_active IP Right Cessation
- 2001-06-08 BG BG105582A patent/BG65149B1/bg unknown
- 2001-06-08 MA MA26228A patent/MA25325A1/fr unknown

Also Published As

Publication number	Publication date
TWI267385B (en)	2006-12-01
IS2370B (is)	2008-06-15
WO2000027364A1 (en)	2000-05-18
AU762410B2 (en)	2003-06-26
DE69910604T2 (de)	2004-06-24
NO20012314L (no)	2001-07-09
UA57165C2 (uk)	2003-06-16
JP2003517446A (ja)	2003-05-27
EE200100254A (et)	2002-12-16
KR100467384B1 (ko)	2005-01-24
CZ20011627A3 (cs)	2001-10-17
EP1128819A1 (en)	2001-09-05
EA005074B1 (ru)	2004-10-28
ES2204193T3 (es)	2004-04-16
SK284758B6 (sk)	2005-11-03
DE69910604D1 (de)	2003-09-25
PL195780B1 (pl)	2007-10-31
NO20012314D0 (no)	2001-05-10
PT1128819E (pt)	2003-12-31
EA200100538A1 (ru)	2001-10-22
BG105582A (en)	2001-12-29
CN1326339A (zh)	2001-12-12
SI1128819T1 (en)	2003-12-31
HRP20010333A2 (en)	2003-04-30
GEP20022833B (en)	2002-11-25
KR20010075695A (ko)	2001-08-09
AU1436600A (en)	2000-05-29
TWI222879B (en)	2004-11-01
CA2350061A1 (en)	2000-05-18
MY122195A (en)	2006-03-31
AR027815A1 (es)	2003-04-16
NZ511430A (en)	2003-05-30
RS49891B (sr)	2008-08-07
ZA200103575B (en)	2002-05-03
MA25325A1 (fr)	2001-12-31
CN1169522C (zh)	2004-10-06
HRP20010333B1 (en)	2004-10-31
YU33101A (sh)	2003-10-31
NO331399B1 (no)	2011-12-19
DK1128819T3 (da)	2003-12-01
US6911217B1 (en)	2005-06-28
IL142809A0 (en)	2002-03-10
SE9803871D0 (sv)	1998-11-11
HK1040917A1 (en)	2002-06-28
HK1040917B (zh)	2005-05-27
EP1128819B1 (en)	2003-08-20
PL348612A1 (en)	2002-06-03
EE05232B1 (et)	2009-12-15
IS5936A (is)	2001-05-09
ATE247458T1 (de)	2003-09-15
AP2001002166A0 (en)	2001-06-30
HUP0105038A2 (en)	2002-06-29
CZ299582B6 (cs)	2008-09-10
AP1323A (en)	2004-11-05
SK6252001A3 (en)	2002-01-07
BR9915142A (pt)	2001-08-07
HUP0105038A3 (en)	2006-07-28
ID30039A (id)	2001-11-01
CA2350061C (en)	2005-05-17
BRPI9915142B8 (pt)	2021-05-25
BG65149B1 (bg)	2007-04-30
JP3616011B2 (ja)	2005-02-02
HU226582B1 (en)	2009-04-28
BRPI9915142B1 (pt)	2015-08-25

Publication	Publication Date	Title
AU762410B2 (en)	2003-06-26	New controlled release bead, a method of producing the same and multiple unit formulation comprising it
EP1227806B1 (en)	2005-08-03	Pharmaceutical formulation containing tolterodine and its use
ME00850B (me)	2008-08-07	Nove perle sa kontrolisanim oslobađanjem, postupak za njihovu proizvodnju i višestruka jedinična formulacija koja ih sadrži
US5834024A (en)	1998-11-10	Controlled absorption diltiazem pharmaceutical formulation
MXPA01004789A (en)	2002-07-25	New controlled release bead, a method of producing the same and multiple unit formulation comprising it